The Transnational Access 1 (TNA1) «Cross platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «will combine the expertise of six different partners (IME, SSI, UOXF, iBET, BPRC and UNISI) to provide the unique offer to test vaccine candidates in a comprehensive
range of different expression
hosts, to
identify the optimal production system for further pre-clinical and clinical development.